MedTrace Logo

Metabolic Characteristics of Brain Tumors Using Hyperpolarized Carbon-13 Magnetic Resonance Spectroscopic Imaging (MRSI)

NCT03067467 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 25

Last updated 2026-03-10

No results posted yet for this study

Summary

This is a non-randomized, purely observational, feasibility study to detect metabolic changes in patients with brain malignancy using a novel hyperpolarized \[1-13C\]pyruvate MRSI.

Conditions

  • Brain Tumor Adult

Interventions

DRUG

Hyperpolarized 13C-Pyruvate

Hyperpolarized 13C-pyruvate IV bolus followed by brain MRSI.

DRUG

Gadolinium

Brain MRI performed with and without gadolinium-based contrast.

Sponsors & Collaborators

  • University of Texas Southwestern Medical Center

    lead OTHER

Principal Investigators

  • Jae Mo Park, PhD · UT Southwestern

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-06-01
Primary Completion
2026-12-31
Completion
2026-12-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03067467 on ClinicalTrials.gov